The latest price target for Petros Pharma (NASDAQ:PTPI) was reported by Maxim Group on December 8, 2023. The analyst firm set a price target for $4.00 expecting PTPI to rise to within 12 months (a possible 846.75% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Petros Pharma (NASDAQ:PTPI) was provided by Maxim Group, and Petros Pharma initiated their buy rating.

There is no last upgrade for Petros Pharma

There is no last downgrade for Petros Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Petros Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Petros Pharma was filed on December 8, 2023 so you should expect the next rating to be made available sometime around December 8, 2024.

While ratings are subjective and will change, the latest Petros Pharma (PTPI) rating was a initiated with a price target of $0.00 to $4.00. The current price Petros Pharma (PTPI) is trading at is $0.42, which is within the analyst’s predicted range.